Trial Profile

AN OPEN-LABEL EXTENSION AND SAFETY MONITORING STUDY OF MODERATE TO SEVERE ULCERATIVE COLITIS PATIENTS PREVIOUSLY ENROLLED IN ETROLIZUMAB PHASE II/III STUDIES

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 25 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Etrolizumab (Primary)
Indications Ulcerative colitis
Focus Adverse reactions; Therapeutic Use
Acronyms COTTONWOOD
Sponsors Roche

Most Recent Events

15 May 2024 This study has been discontinued in Estonia, according to European Clinical Trials Database record.
28 Mar 2024 This study has been discontinued in Portugal, according to European Clinical Trials Database record.
30 Oct 2023 Status changed from active, no longer recruiting to discontinued.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com